KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Korsana Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$31.41−0.97 (-3.00%)
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$15.73 (+100.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Korsana Biosciences, Inc. saw revenue fall 12.6% to $1.90M over the twelve months to Jun 30, 2026.
Revenue
$1.90M
-12.6% vs. a year earlier
Operating income
-$6.82M
TTM Q2 2026
EPS, diluted
-$1.68
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $133.52M
- P/E ratio
- –
- Price to sales
- 70.28
- Price to book
- 26.25
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.90M
- Net income
- -$6.71M
- EPS, diluted
- -$1.68
- Book value per share
- $1.20
- Diluted shares
- 4M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$1.90M-12.6% YoY
Operating income
-$6.82M
Net income
-$6.71M
EPS, diluted
-$1.68
Free cash flow
–
Reported periodTrailing twelve months